82 related articles for article (PubMed ID: 8123940)
21. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
22. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
23. Oestrogen causes G2/M arrest and apoptosis in breast cancer cells MDA-MB-231.
Nomoto S; Arao Y; Horiguchi H; Ikeda K; Kayama F
Oncol Rep; 2002; 9(4):773-6. PubMed ID: 12066207
[TBL] [Abstract][Full Text] [Related]
24. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
25. Physalis angulata induced G2/M phase arrest in human breast cancer cells.
Hsieh WT; Huang KY; Lin HY; Chung JG
Food Chem Toxicol; 2006 Jul; 44(7):974-83. PubMed ID: 16427178
[TBL] [Abstract][Full Text] [Related]
26. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells.
Choi EJ; Kim GH
Phytomedicine; 2008 Sep; 15(9):683-90. PubMed ID: 18541420
[TBL] [Abstract][Full Text] [Related]
27. Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines.
Nakagawa H; Yamamoto D; Kiyozuka Y; Tsuta K; Uemura Y; Hioki K; Tsutsui Y; Tsubura A
J Cancer Res Clin Oncol; 2000 Aug; 126(8):448-54. PubMed ID: 10961387
[TBL] [Abstract][Full Text] [Related]
28. Differential responsiveness of human breast cancer cells to basic fibroblast growth factor: a cell kinetics study.
Delehedde M; Boilly B; Hondermarck H
Oncol Res; 1995; 7(7-8):399-405. PubMed ID: 8747603
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
Locke V; Davey R; Davey M
Cytometry; 2001 Mar; 43(3):170-4. PubMed ID: 11170102
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
31. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells.
Zhang W; Ling V
J Cell Physiol; 2000 Jul; 184(1):17-26. PubMed ID: 10825230
[TBL] [Abstract][Full Text] [Related]
32. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
33. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
34. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells.
Gooch JL; Herrera RE; Yee D
Cell Growth Differ; 2000 Jun; 11(6):335-42. PubMed ID: 10910100
[TBL] [Abstract][Full Text] [Related]
35. beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism.
Awad AB; Barta SL; Fink CS; Bradford PG
Mol Nutr Food Res; 2008 Apr; 52(4):419-26. PubMed ID: 18338406
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM
Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048
[TBL] [Abstract][Full Text] [Related]
37. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.
Kirk J; Houlbrook S; Stuart NS; Stratford IJ; Harris AL; Carmichael J
Eur J Cancer; 1993; 29A(8):1152-7. PubMed ID: 8518026
[TBL] [Abstract][Full Text] [Related]
38. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.
DeGregorio MW; Ford JM; Benz CC; Wiebe VJ
J Clin Oncol; 1989 Sep; 7(9):1359-64. PubMed ID: 2527971
[TBL] [Abstract][Full Text] [Related]
39. Toremifene resistance in a rat mammary tumour model.
Kellen JA; Georges E; Ling V; Dubsky M
Anticancer Res; 1992; 12(5):1663-5. PubMed ID: 1359832
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype.
Martin JH; Symonds A
Oncol Rep; 2002; 9(2):379-82. PubMed ID: 11836612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
